Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""van Seijen, Maartje"" wg kryterium: Autor


Wyświetlanie 1-18 z 18
Tytuł :
Ductal carcinoma in situ: to treat or not to treat, that is the question.
Autorzy :
van Seijen M; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Thompson AM; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.
Nik-Zainal S; Department of Medical Genetics, University of Cambridge, Cambridge, UK.
Futreal A; Department of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hwang ES; Department of Surgery, Duke University Comprehensive Cancer Center, Durham, NC, USA.
Verschuur E; Borstkankervereniging Nederland, Utrecht, The Netherlands.
Lane J; Health Cluster Net, Amsterdam, The Netherlands.
Jonkers J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Oncode Institute, Amsterdam, The Netherlands.
Rea DW; Department of Medical Oncology, University of Birmingham, Birmingham, UK.
Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. .; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands. .; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. .
Pokaż więcej
Corporate Authors :
PRECISION team
Źródło :
British journal of cancer [Br J Cancer] 2019 Aug; Vol. 121 (4), pp. 285-292. Date of Electronic Publication: 2019 Jul 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Breast Neoplasms/*therapy
Carcinoma, Intraductal, Noninfiltrating/*therapy
Breast Neoplasms/epidemiology ; Breast Neoplasms/etiology ; Carcinoma, Intraductal, Noninfiltrating/epidemiology ; Carcinoma, Intraductal, Noninfiltrating/etiology ; Female ; Humans
Czasopismo naukowe
Tytuł :
Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen.
Autorzy :
van Seijen M; Department of Pathology, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, The Netherlands.; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Brcic L; Institute of Pathology, Medical University of Graz, Graz, Austria.
Gonzales AN; Valencia Hospital General Universitario, Valencia, Spain.
Sansano I; Vall d'Hebron University Hospital Barcelona, Spain, Barcelona, Spain.
Bendek M; National Institute of Pulmonary Medicine Budapest, Budapest, Hungary.; Department of Pathology, Karolinska University Hospital, Stockholm, Sweden.
Brcic I; Institute of Pathology, Medical University of Graz, Graz, Austria.
Lissenberg-Witte B; Department of Epidemiology and Biostatistics, Amsterdam UMC, VU University Medical Center, Amsterdam, The Netherlands.
Korkmaz HI; Department of Pathology, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, The Netherlands.
Geiger T; ETOP Bern, Bern, Switzerland.
Kammler R; ETOP Bern, Bern, Switzerland.
Stahel R; ETOP Bern, Bern, Switzerland.; University Hospital of Zurich, Zurich, Switzerland.
Thunnissen E; Department of Pathology, Amsterdam University Medical Centers, VU University Medical Center, Amsterdam, The Netherlands. .
Pokaż więcej
Corporate Authors :
ETOP
Źródło :
Virchows Archiv : an international journal of pathology [Virchows Arch] 2019 Aug; Vol. 475 (2), pp. 191-199. Date of Electronic Publication: 2019 Jul 01.
Typ publikacji :
Journal Article
MeSH Terms :
Biomarkers, Tumor/*analysis
Carcinoma, Non-Small-Cell Lung/*pathology
Immunohistochemistry/*methods
Lung Neoplasms/*pathology
Tissue Fixation/*methods
Humans ; Staining and Labeling/methods
Czasopismo naukowe
Tytuł :
Impact of delayed and prolonged fixation on the evaluation of immunohistochemical staining on lung carcinoma resection specimen
Autorzy :
van Seijen, MaartjeAff1, Aff2
Brcic, Luka
Gonzales, Atilio Navarro
Sansano, Irene
Bendek, MatyasAff6, Aff7
Brcic, Iva
Lissenberg-Witte, Birgit
Korkmaz, H. Ibrahim
Geiger, Thomas
Kammler, Rosita
Stahel, RolfAff9, Aff10
Thunnissen, Erik
On behalf of ETOP
Pokaż więcej
Źródło :
Virchows Archiv: European Journal of Pathology. 475(2):191-199
Czasopismo naukowe
Tytuł :
Prognostic Value of Residual Disease after Neoadjuvant Therapy in HER2-Positive Breast Cancer Evaluated by Residual Cancer Burden, Neoadjuvant Response Index, and Neo-Bioscore.
Autorzy :
Steenbruggen TG; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
van Seijen M; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Janssen LM; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
van Ramshorst MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
van Werkhoven E; Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Vrancken Peeters MTDF; Department of Surgical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Wesseling J; Department of Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Lips EH; Department of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.
Sonke GS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands. .
Pokaż więcej
Źródło :
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2019 Aug 15; Vol. 25 (16), pp. 4985-4992. Date of Electronic Publication: 2019 May 10.
Typ publikacji :
Journal Article
MeSH Terms :
Breast Neoplasms/*mortality
Breast Neoplasms/*pathology
Neoplasm, Residual/*pathology
Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor ; Breast Neoplasms/drug therapy ; Breast Neoplasms/metabolism ; Chemotherapy, Adjuvant ; Combined Modality Therapy ; Disease Progression ; Female ; Humans ; Middle Aged ; Neoadjuvant Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Neoplasm, Residual/metabolism ; Netherlands ; Receptor, ErbB-2/metabolism ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Feasibility of Micro-Computed Tomography Imaging for Direct Assessment of Surgical Resection Margins During Breast-Conserving Surgery.
Autorzy :
Janssen NNY; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands. Electronic address: .
van Seijen M; Department of Molecular Pathology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Loo CE; Department of Radiology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Vrancken Peeters MTFD; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Hankel T; Department of Technical Medicine, University of Twente, Enschede, the Netherlands.
Sonke JJ; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Nijkamp J; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
Pokaż więcej
Źródło :
The Journal of surgical research [J Surg Res] 2019 Sep; Vol. 241, pp. 160-169. Date of Electronic Publication: 2019 Apr 23.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Margins of Excision*
Mastectomy, Segmental*
Breast/*diagnostic imaging
Breast Neoplasms/*surgery
Adult ; Aged ; Aged, 80 and over ; Breast/pathology ; Breast/surgery ; Breast Neoplasms/diagnostic imaging ; Breast Neoplasms/pathology ; Feasibility Studies ; Female ; Humans ; Middle Aged ; Netherlands ; Observer Variation ; Postoperative Period ; Prospective Studies ; Retrospective Studies ; Sensitivity and Specificity ; X-Ray Microtomography
Czasopismo naukowe
Tytuł :
The impact of patient characteristics and lifestyle factors on the risk of an ipsilateral event after a primary DCIS: A systematic review.
Autorzy :
Alaeikhanehshir S; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Engelhardt EG; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
van Duijnhoven FH; Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
van Seijen M; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Bhairosing PA; Scientific Information Service, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Pinto D; Patient Advocate Involvement Panel (PAIP), PRECISION PROJECT, United Kingdom.
Collyar D; Patient Advocate Involvement Panel (PAIP), PRECISION PROJECT, United Kingdom.
Sawyer E; School of Cancer and Pharmaceutical Sciences, Guy's Hospital, King's College London, London, United Kingdom.
Hwang SE; Department of Surgery, Duke University Medical Centre, Duke Cancer Institute, Durham, NC, United States.
Thompson AM; Dan L Duncan Comprehensive Cancer Centre, Baylor College of Medicine, Houston, TX, United States.
Wesseling J; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Department of Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands. Electronic address: .
Schmidt MK; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
Pokaż więcej
Corporate Authors :
PRECISION
Źródło :
Breast (Edinburgh, Scotland) [Breast] 2020 Apr; Vol. 50, pp. 95-103. Date of Electronic Publication: 2020 Feb 19.
Typ publikacji :
Journal Article; Systematic Review
MeSH Terms :
Disease Progression*
Life Style*
Breast Neoplasms/*epidemiology
Carcinoma, Intraductal, Noninfiltrating/*epidemiology
Breast Neoplasms/therapy ; Carcinoma, Intraductal, Noninfiltrating/therapy ; Female ; Humans ; Observational Studies as Topic ; Randomized Controlled Trials as Topic ; Risk Factors ; Watchful Waiting
Czasopismo naukowe
Tytuł :
Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials.
Autorzy :
Hudeček J; 1Department of Research IT, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Voorwerk L; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van Seijen M; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Nederlof I; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
de Maaker M; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van den Berg J; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
van de Vijver KK; 5Department of Pathology, Ghent University Hospital, Ghent, Belgium.
Sikorska K; 6Department of Biometrics, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Adams S; 7Department of Medicine, Perlmutter Cancer Center, New York University School of Medicine, New York, NY USA.
Demaria S; 8Department of Radiation Oncology, Weill Cornell Medicine, New York, NY USA.; 9Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, NY USA.
Viale G; 10International Breast Cancer Study Group Central Pathology Office, Department of Pathology and Laboratory Medicine, IEO European Institute of Oncology IRCCS, Milan, Italy.; 11University of Milan, Milan, Italy.
Nielsen TO; 12Department of Pathology and Laboratory Medicine, Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC Canada.
Badve SS; 13Department of Pathology and Laboratory Medicine, Indiana University Simon Cancer Center, Indianapolis, IN USA.
Michiels S; 14Service de Biostatistique et d'Epidémiologie, Gustave Roussy, CESP, Université-Paris Sud, Université Paris-Saclay, Villejuif, France.; 15CESP, Fac. de médecine - Univ. Paris-Sud, Fac. de médecine - UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.
Symmans WF; 16Department of Pathology, M.D. Anderson Cancer Center, Houston, TX USA.
Sotiriou C; 17Breast Cancer Translational Research Laboratory, Institut Jules Bordet, U-CRC, Université Libre de Bruxelles, Brussels, Belgium.
Rimm DL; 18Department of Pathology, Yale School of Medicine, New Haven, CT USA.; 19Department of Medicine, Yale University School of Medicine, New Haven, CT USA.
Hewitt SM; 20Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD USA.
Denkert C; 21Institute of Pathology, Charité Universitätsmedizin Berlin, Berlin, Germany.; 22Institute of Pathology, Philipps-University Marburg, Marburg, Germany.
Loibl S; 23German Breast Group, Neu-Isenburg, Germany.
Loi S; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.
Bartlett JMS; 25Ontario Institute for Cancer Research, Toronto, ON Canada.; 26IGMM, Edinburgh, UK.; 27Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK.
Pruneri G; 28Department of Pathology and Laboratory Medicine, IRCCS Fondazion - Instituto Nazionale Tumori, Milan, Italy.; 29School of Medicine, University of Milan, Milan, Italy.
Dillon DA; 30Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA USA.
Cheang MCU; 31Clinical Trials and Statistics Unit, The Institute of Cancer Research, Surrey, UK.
Tutt A; 32Breast Cancer Now Toby Robins Research Centre, The Institute of Cancer Research, London, UK.
Hall JA; Research and Development, Vivactiv Ltd, Chesham, Buckinghamshire UK.
Kos Z; 34Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, ON Canada.
Salgado R; 24Division of Research and Clinical Medicine, Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC Australia.; Department of Pathology, GZA-ZNA Ziekenhuizen, Antwerp, Belgium.
Kok M; 2Division of Tumor Biology and Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 36Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Horlings HM; 3Division of Molecular Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; 4Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pokaż więcej
Corporate Authors :
International Immuno-Oncology Biomarker Working Group
Źródło :
NPJ breast cancer [NPJ Breast Cancer] 2020 May 12; Vol. 6, pp. 15. Date of Electronic Publication: 2020 May 12 (Print Publication: 2020).
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast.
Autorzy :
van Seijen M; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Lips EH; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Fu L; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Giardiello D; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
van Duijnhoven F; Department of Surgery, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
de Munck L; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Elshof LE; Department of radiology, Meander Medical Centre, Amersfoort, The Netherlands.
Thompson A; Dan L Duncan Comprehensive Cancer Centre, Baylor College of Medicine, Houston, TX, USA.
Sawyer E; Division of Cancer Studies, King's College London, Comprehensive Cancer Centre, Guy's Hospital, London, UK.
Ryser MD; Department of Population Health Sciences, Duke University, Durham, NC, USA.; Department of Mathematics, Duke University, Durham, NC, USA.
Hwang ES; Department of Surgery, Duke University, Durham, NC, USA.
Schmidt MK; Division of Molecular Pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.; Department of clinical genetics, Leiden University Medical Center, Leiden, The Netherlands.
Elkhuizen PHM; Department of radiotherapy, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Wesseling J; Department of pathology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands. .; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands. .
Schaapveld M; Division of Psychosocial Research and Epidemiology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Pokaż więcej
Corporate Authors :
Grand Challenge PRECISION Consortium
Źródło :
British journal of cancer [Br J Cancer] 2021 Aug 18. Date of Electronic Publication: 2021 Aug 18.
Typ publikacji :
Journal Article
Czasopismo naukowe
    Wyświetlanie 1-18 z 18

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies